CFO of Processa (NASDAQ: PCSA) adds 3,277 shares in open-market buy

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of 3,277 shares of Common Stock at $1.93 per share. After this transaction, he directly owns 16,689 shares. This filing reflects a relatively small insider buy by a senior executive.

Insider Trade Summary

Net Buyer: 3,277 shares ($6,325)

Net Buy 1 txn

Insider SKIBSTED RUSSELL

Role Chief Financial Officer

Bought 3,277 shs ($6K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	3,277	$1.93	$6K

Holdings After Transaction: Common Stock — 16,689 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 3,277 shares Purchase price: $1.93 per share Holdings after transaction: 16,689 shares

3 metrics

Shares purchased 3,277 shares Open-market purchase of Common Stock

Purchase price $1.93 per share Price paid for Common Stock on June 30, 2026

Holdings after transaction 16,689 shares Direct ownership following the reported trade

Key Terms

open-market purchase, Common Stock, Form 4

3 terms

open-market purchase financial

"transaction_action: "open-market purchase" in Common Stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"security_title: "Common Stock" for the reported transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4) for Processa Pharmaceuticals"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 04:18 PM Accepted by SEC EDGAR 07/01/2026 - 04:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SKIBSTED RUSSELL

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2026		P		3,277	A	$1.93	16,689	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Russell Skibsted by John J. Wolfel, as Attorney-in-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Processa Pharmaceuticals (PCSA) report?

Processa Pharmaceuticals reported that its CFO, Russell Skibsted, made an open-market purchase of 3,277 shares of Common Stock at $1.93 per share, increasing his direct holdings to 16,689 shares following the transaction.

Who bought shares of Processa Pharmaceuticals (PCSA) in this Form 4?

Chief Financial Officer Russell Skibsted bought shares in this filing. He acquired 3,277 Processa Pharmaceuticals Common Stock shares in an open-market purchase and now directly owns a total of 16,689 shares after the reported transaction.

How many Processa Pharmaceuticals (PCSA) shares did the CFO purchase?

The CFO purchased 3,277 shares of Processa Pharmaceuticals Common Stock. These shares were acquired in an open-market transaction at a price of $1.93 per share, as reported in the Form 4 insider filing data.

At what price were Processa Pharmaceuticals (PCSA) shares bought in this insider trade?

The reported insider trade shows an open-market purchase at $1.93 per share. CFO Russell Skibsted acquired 3,277 shares of Processa Pharmaceuticals Common Stock at this price in the transaction dated June 30, 2026.

What are the CFO’s total Processa Pharmaceuticals (PCSA) holdings after the transaction?

Following the reported purchase, the CFO directly owns 16,689 shares of Processa Pharmaceuticals Common Stock. This total reflects his position after acquiring 3,277 additional shares in the open-market transaction disclosed in the Form 4.